Work on the purification of the substrate in plasma for kinin-forming enzymes, kininogen, has been carried out in several laboratories. Habermann (1963) thus purified kininogen from bovine serum and Suzuki, Mizushima, Sato & Iwanaga (1965) purified a kininogen from bovine plasma. Habermann (1965Habermann ( , 1966 also studied the structure of the kinin-yielding polypeptides of his purified bovine kininogen (peptic kinin-yielding polypeptides). Pierce & Webster (1966) isolated two kininogens from human plasma. These kininogens were shown to be glycoproteins with molecular weights of about 50,000, as is also the case with the bovine kininogen (Habermann, 1963). Jacobsen (1966b) found that two different substrates for plasma kinin-forming enzymes could be separated from plasmas of several mammals. These substrates had different molecular dimensions and they differed in their reaction patterns towards various kininforming enzymes. The present paper reports the results of further purification with some characterization of these two substrates. The substrate with the larger molecular dimension has been designated substrate 1, and the other and smaller one has been designated substrate 2. The methods employed have been DEAE anion exchange chromatography, gel filtration, disc gel electrophoresis and sucrose gradient ultracentrifugation. METHODS Plasma. Citrated human plasma was obtained by using siliconized equipment throughout, as described by Jacobsen (1966b).Initial purification procedures for kininogens (anion exchange chromatography and gel filtration). The separation procedures previously described (Jacobsen, 1966a(Jacobsen, , 1966b have been modified and expanded, so as to include disc gel electrophoresis (see below). The initial procedure was a separation of fractions containing the two kininogens by chromatography of human citrated plasma on a DEAE anion exchanger. Each of the substrates was subsequently exposed to further purification procedures (see below and Table 1). For initial chromatography, plasma (25 ml.) was mixed with 0.05 M Tris-HCl buffer (pH 8) containing 0.25 M sodium chloride (12.5 ml.) and the mixture applied to a DEAE-Sephadex A 50 (A. B. Pharmacia, Uppsala, Sweden) column (18 x 1.8 cm) equilibrated with 0.05 M Tris-HCl buffer (pH 8) containing 0.2 M sodium chloride. Substrate 1 is retained on the column while substrate 2 is eluted with the equilibrating buffer. Substrate 1 could then be eluted with a 0.05 M Tris-HCl buffer (pH 8) containing 0.35 M sodium chloride. The effluent containing substrate 2 was treated with " massive contact exposure " in order to eliminate the plasma kallikrein activity (Jacobsen, 1966b), and then applied to a DEAE-Sephadex A 50 column (10 x 1 cm) equilibrated with 0.05 M Tris-HCI buffer (pH 8) containing 0.1 M sodium chloride. Substrate 2 was eluted from this column with a buffer containing 0.25 M sodium chloride. Buffer concentrations in the samples were always adjusted to that of the buffer used for equilibration in the following purification procedure.
S. JACOB...